Primary Job Title Co-founder, Chairman & Chief Executive Officer Primary Organization 
MolecularMD
Gender Male
LinkedIn View on LinkedIn
Sheridan Snyder, LLB (Hon) is the Chairman and Chief Executive Officer at MolecularMD.
Dr. Sheridan Gray "Sherry" Snyder OBE, LLB (born October 20, 1936), often referred to as Sherry Snyder, is an entrepreneurial figure in the biotechnology industry and a philanthropist, who has also made significant contributions to the development of
the game of tennis.
Mr. Snyder graduated from The Lawrenceville School in New Jersey and is a 1958 graduate of The University of Virginia with a Bachelor of Arts in French & Romance Languages. At UVa, Snyder was a member of the SPE social fraternity. Snyder received an Honorary Doctorate of Law degree from the University of Dundee in 2002.
Upon graduation from UVA, Snyder began his career as a Credit Analyst for New York Trust Corporation. In 1962, Snyder founded his first venture, Cambridge Machine Corporation, which initiated the development and invention of high-speed mailing/envelope inserting machines. In 1971, Snyder founded a packaging company, Instapak, which markets “foam-in-place packaging” (revolutionary for its time) that creates a protective barrier for heavy, fragile instrumentation and computer systems. Snyder sold Cambridge Machine Corporation to Pitney-Bowes and he became the National Sales Account manager at Pitney-Bowes. Instapak is now the largest division of Sealed Air Corporation (NYSE: SEE), with more than 5,500 employees and revenues of $1 billion.
In 1981, Mr. Snyder founded Genzyme and served as Chairman/President/CEO.
Mr. Snyder founded Biotage in 1989 which focuses on the development of novel drug development systems. Biotage was acquired by the Swedish biotechnology company Pyrosequencing in 2004 which then took the name Biotage AB.
In 1994 Snyder founded Argonex a small biotech start-up in Charlottesville, VA. In 1996, Mr. Snyder founded and served as Chairman and Chief Executive Officer Upstate Biotechnology Incorporated merging it with Argonex. Upstate Inc. develops innovative cell signaling products, technology platforms and services to accelerate life science research and drug discovery efforts. Upstate was sold to Serologicals Corporation in 2004 for $205 Million.
Biocatalyst International is the most recent of Mr. Snyder’s business enterprises, founded in 2005. Spearheaded by Sherry, Biocatalyst creates sustainable biotech companies in partnership with leading scientists.
Biocatalyst International to date incorporates three dynamic companies interfacing with diverse markets of the biotechnology world. These three corporations were founded by Mr. Snyder, as he takes the biotechnology industry into the future. Biocatalyst International, Molecular MD and Xcovery are leading forces catapulting profitable biotech start-up ventures and expanding the boundaries of science today.
Mr. Snyder co-founded Xcovery with Dr. Chris Liang, Director of Medicinal Chemistry, Scripps Research Florida, and co-developer of Sutent, Pfizer’s first small molecule oncology drug. Xcovery has 5 lead compounds focused on cancer.
Molecular MD was co-founded with Dr. Brian Druker, inventor of Gleevec, Director of the Cancer Center at the Oregon Health Sciences University in Portland. Oregon. Gleevec is a revolutionary small molecule drug that prevents and stops the growth of cancer cells in chronic myeloid leukemia (CML). MMD is a molecular diagnostic company in the world of personalized medicine utilizing highly sensitive detection systems.
